sponsored
PatientsVille.com Logo

PatientsVille

ENBREL Medical Research Studies

Up-to-date List of ENBREL Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest ENBREL Medical Research Studies

Rank Status Study
1 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
2 Not yet recruiting Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
Condition: Rheumatoid Arthritis
Interventions: Biological: Etanercept;   Biological: CHS-0214
Outcome Measure: ACR-20
3 Recruiting Etanercept in Kawasaki Disease
Conditions: Mucocutaneous Lymph Node Syndrome;   Kawasaki Disease
Interventions: Drug: Etanercept;   Drug: Placebo
Outcome Measures: Determine if Etanercept at the dosing regimen of 0.8 mg/kg (50 mg max) SQ X3 doses given at weekly intervals, when used in conjunction with IVIG and aspirin will reduce the incidence of fever persistence or recrudescence.;   Determine if the safety profile differs between the etanercept treated group and the placebo group.;   Determine if Etanercept treatment alters the rate of coronary artery dilation and disease (CAD) defined by z-scores at 2 and 6 weeks after treatment.;   Determine the pharmacokinetics of Etanercept in KD patients.
4 Unknown  Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: etanercept
Outcome Measures: Flare-rate;   Duration of remission before withdrawal of etanercept;   Predictors for successful discontinuation of etanercept;   Disease course after flaring
5 Recruiting Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: Etanercept;   Dietary Supplement: Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Outcome Measures: Difference in effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Mini-Mental Status Examination (MMSE) score.;   Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) score.;   Difference in the effects of treatment for 6 weeks with etanercept + nutritional supplements versus nutritional supplements alone on the Montreal Cognitive Assessment (MoCA) score.
6 Not yet recruiting Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
Condition: Plaque Psoriasis
Interventions: Biological: Etanercept;   Drug: CHS-0214
Outcome Measure: PASI-75
7 Not yet recruiting Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage
Condition: Subarachnoid Hemorrhage, Aneurysmal
Intervention: Drug: Etanercept
Outcome Measures: Safety, blood brain barrier (BBB) permeability and potential efficacy of the TNFa antagonist, etanercept, in humans with subarachnoid hemorrhage (SAH).;   Pharmacokinetics (plasma and CSF concentrations) of etanercept by measuring daily plasma and CSF concentrations by enzyme-linked immunosorbent assay (ELISA).
8 Recruiting Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis
Conditions: Inflammation;   Ankylosing Spondylitis
Interventions: Drug: celebrex;   Drug: Enbrel;   Drug: Enbrel plus Celebrex
Outcome Measures: the SPARCC score of spine and SI joint;   mSASSS score of spine;   ASAS20 response rate;   ASAS20 response;   ASAS40 response;   ASAS70 response;   ASAS5/6 response
9 Unknown  The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus
Condition: Discoid Lupus Erythematosus (DLE)
Intervention: Drug: etanercept(Enbrel®)
Outcome Measures: Proportion of patients responding to study treatment using the Cutaneous Lupus Erythematous Disease Area Severity Index(CLASI)defined as a decrease of 50% form baseline.;   Change from baseline to week 20 in Dermatology Life Quality Index and Pysician's Global Assessment of disease measurements
10 Recruiting Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
Condition: Moderate to Severe Rheumatoid Arthritis
Intervention: Biological: etanercept
Outcome Measures: To evaluate the efficacy of etanercept in adult subjects with moderate to severe rheumatoid arthritis who failed to respond or responded and then lost response to adalimumab as first biologic agent.;   Determine if anti-adalimumab antibodies predict response to etanercept, to determine if adalimumab failures predict response to etanercept, and to evaluate the effects of etanercept
11 Unknown  Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)
Condition: Moderate to Severe Active Axial Spondyloarthritis
Interventions: Drug: Etanercept 25mg;   Drug: Sulfasalazine
Outcome Measures: Primary outcome: Reduction of active inflammatory lesions in MRI at 12 months.;   Secondary outcome: ASAS 20%, 40%, 70% response, ASAS criteria for partial remission· BASDAI 20%, 50%, 70% improvement · BASFI ·
12 Unknown  Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
Conditions: Behcet Syndrome;   Uveal Disease
Intervention: Drug: Etanercept, Methotrexate, Prednisolone
Outcome Measures: Visual Acuity, Disease Activity Index (DAI) for Posterior Uveitis, DAI for Retinal vasculitis;   DAI for Anterior Uveitis, Total Inflammatory Acitivity Index, Total Adjusted Disease Activity Index
13 Recruiting An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria
Condition: Plaque Psoriasis Patients
Intervention: Other: Enbrel treatment
Outcome Measures: Average treatment duration of patients with Enbrel expressed as a number of weeks/year.;   Number of patients who receive continuous treatment;   Number of patients who receive intermittent treatment;   Number of weeks off treatment
14 Recruiting Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
Condition: Psoriasis
Intervention: Drug: etanercept
Outcome Measures: Efficacy of etanercept;   Safety of etanercept;   Evaluate and compare efficacy and safety in subjects with and without antibodies to adalimumab;   Effect of treatment with etanercept on patient reported outcomes
15 Recruiting Effects of Denosumab on the Pharmacokinetics of Etanercept
Conditions: Postmenopausal;   Osteopenia;   Rheumatoid Arthritis;   Osteoporosis
Interventions: Drug: Etanercept;   Drug: Denosumab
Outcome Measures: Area under the serum concentration-time curve (AUC) from 0 to 168 hours for etanercept.;   Maximum observed serum concentration (Cmax) for etanercept.;   Time to maximum serum concentration (tmax) for etanercept.;   Serum denosumab concentration.;   Serum C-telopeptide (sCTx) concentrations.
16 Recruiting Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis
Condition: Psoriasis
Intervention: Drug: Etanercept
Outcome Measures: Number of SAEs including serious infections and malignancy;   Effectiveness or lack of effectiveness will be inferred from the number of 24 week courses the patient completes
17 Recruiting Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: Etanercept;   Drug: Etnaercept;   Drug: Placebo
Outcome Measures: Change from Baseline in Disease Activity Score Based on 28-joints Count (DAS28);   Number of Participants with DAS28 <3.2;   Number of Participants with DAS28 <2.6;   Number of Participants Acheiving American College of Rheumatology 20% (ACR20) Response;   Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response;   Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response;   Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response;   Number of Participants Acheiving European League against Rheumatism (EULAR) Good and/or Moderate Response;   Number of Participants Acheiving Low Disease Activity or Remission Based on Clinical Disease Activity Index (CDAI);   Number of Participants Acheiving Low Disease Activity or Remission Based on Simplified Disease Activity Index (SDAI);   Change from Baseline in Clinical Disease Activity Index (CDAI);   Change from Baseline in Simplified Disease Activity Index (SDAI);   Change from Baseline in Number of Tender/Painful Joints;   Change from Baseline in Number of Swollen Joints;   Change from Baseline in Physician Global Assessment (PGA) of Disease Activity;   Change from Baseline in Subject Global Assessment of Disease Activity;   Change from Baseline in Subject General Health;   Change from Baseline in Subject Pain;   Change from Baseline in C-Reactive Protein (CRP);   Change from Baseline in Health Assessment Questionnaire Disability and Discomfort Scales (HAQ-DI);   Change from Baseline in Euro Qol EQ-5 Dimensions Questionnaire (EQ-5D);   Change from Baseline in Short Form-36 Health Survey (SF-36);   Change from Baseline in Patient Acceptable Symptom State (PASS);   Change from Baseline in Vectra disease activity (DA) levels;   Number of Participants with Positive Etanercept Anti-drug Antibody Status;   Number of Participants with Positive Etanercept Neutralizing Anti-drug Antibody Status
18 Not yet recruiting Etanercept in Rheumatoid Arthritis and Vascular Inflammation
Conditions: Rheumatoid Arthritis;   Vascular Inflammation
Intervention: Drug: etanercept
Outcome Measures: Target to background ratio (TBR) from the ascending aorta;   TBR from the mean of both carotid arteries;   High Sensitivity C-reactive protein (hsCRP);   Count of swollen and tender joints;   Correlation of TBR from the ascending aorta with hsCRP;   Correlation of TBR from the mean of both carotid arteries with hsCRP;   Correlation of TBR from the ascending aorta with swollen and tender joint count;   Correlation of TBR from the carotid arteries with swollen and tender joint count
19 Not yet recruiting Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of Enbrel 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers
Condition: Rheumatoid Arthritis
Interventions: Drug: DWP422 25mg;   Drug: Enbrel 25MG PFS INJ.
Outcome Measure: Etanercept levels in blood
20 Recruiting Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction
Condition: Myocardial Infarction
Interventions: Drug: Etanercept;   Drug: saline
Outcome Measures: Composite of major adverse cardiovascular events (MACE) consisting of cardiovascular death, fatal myocardial infarction and fatal stroke;   Composite endpoint of major cardiovascular events, non-elective coronary revascularization procedures and hospitalization for unstable angina Cardiovascular death Non-fatal myocardial infarction Non-fatal stroke of all classifications;   Elevation of ALT, AST and CK;   serum adiponectin concentration, activity and isoforms

These studies may lead to new treatments and are adding insight into ENBREL etiology and treatment.

A major focus of ENBREL research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss ENBREL